🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — June 11, 2026

Overnight filings reveal a market bifurcated between aggressive capital markets activity and operational caution. The most dominant theme is the surge in SPAC and M&A activity, with major transactions including Dana/Eaton's $5.1B Reverse Morris Trust deal, GameStop's $125/share proposal for eBay, and multiple SPAC combinations (General Fusion, Quantum Space, Ignite Proteomics, Freenome). Period-over-period data shows a stark contrast: GameStop's net income surged 770% YoY on a derivative gain, while biotech Kardigan's losses tripled and Lovesac's losses widened. Capital allocation is mixed—CoreWeave seeks $3.5B in debt, PureCycle launches a $395M convertible/equity offering, while News Corp continues its $1B buyback. Insider activity is limited but notable, with Seer facing a proxy fight and Sentinel Holdings changing auditors after a going concern qualification. The healthcare sector shows strong clinical data (Nurix 83% ORR in CLL) alongside high cash burn rates, while the energy transition theme gains momentum with ONE Nuclear Energy targeting 15 GW by 2033. Overall, the market is pricing in risk-on sentiment for high-growth stories but punishing companies with deteriorating fundamentals.

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — June 10, 2026

This digest covers five FDA approvals on June 10, 2026, all classified as 'Other' (biosimilar/generic fallback) with zero NMEs, zero label expansions, and zero biosimilar designations explicitly flagged. The dominant theme is a concentrated wave of tofacitinib citrate biosimilar approvals—four entrants (SPECGX LLC, MACLEODS PHARMS LTD, APOTEX, and MSN) all approved on June 3, 2026—plus a single macitentan biosimilar from TEVA PHARMS USA INC on June 8. The highest-conviction signal is the tofacitinib citrate cluster: the simultaneous entry of four biosimilar competitors into the JAK inhibitor market signals imminent and severe pricing erosion for Pfizer’s Xeljanz (tofacitinib), which faces both IRA negotiation risk (small molecule, year 9) and now multiple generic entrants. The key risk is that these approvals are 'FALLBACK' type, suggesting they may not be full interchangeable biosimilars, potentially limiting immediate market share capture, but the sheer number of entrants still pressures originator revenue. No bullish signals were identified; all five approvals are neutral for the sponsors but bearish for originator Pfizer.

5 total filings
· daily

Big Pharma Approvals — June 10, 2026

The single FDA approval during this period was a label expansion for Pfizer's MARSTACIMAB-HNCQ (HYMPAVZI), classified as a 'FALLBACK' type with a moderate bullish signal. With zero NMEs, biosimilars, or other label expansions, the digest lacks the high-conviction catalysts typically sought by institutional investors. The approval reinforces Pfizer's commercial execution in an undisclosed therapeutic area but offers limited new competitive or pipeline insight. Key watch items include the absence of peak sales estimates and exclusivity data, which obscure the true commercial materiality of this expansion.

1 total filings
· daily

Orphan Drug Approvals — June 10, 2026

During the single-day period of June 10, 2026, the FDA issued one orphan drug approval, which was a label expansion for Pfizer Inc.’s MARSTACIMAB-HNCQ (HYMPAVZI). No NMEs, biosimilars, or standard label expansions were approved, making this a low-volume but directionally bullish session for Pfizer. The approval reinforces Pfizer’s ability to extend the commercial lifecycle of its existing biologic assets, though the lack of NME or biosimilar activity limits broader sector signals. The key risk is that without disclosed peak sales estimates or exclusivity details, the materiality of this label expansion remains uncertain for investors.

1 total filings
· daily

New Drug Approvals (Original) — June 10, 2026

During the June 10, 2026 snapshot, the FDA approved five non-NME, non-biosimilar, non-label-expansion 'Other' applications, all classified as FALLBACK approvals with neutral signals. The dominant theme is a concentrated wave of four tofacitinib citrate approvals (from SPECGX LLC, MACLEODS PHARMS LTD, APOTEX, and MSN) on June 3, 2026, signaling a coordinated generic/biosimilar entry into the JAK inhibitor market, which poses a bearish competitive risk for originator Pfizer (XELJANZ). The fifth approval, macitentan from TEVA PHARMS USA INC, represents a biosimilar entry against Johnson & Johnson's OPSUMIT, adding further pricing pressure in the pulmonary arterial hypertension (PAH) space. The highest-conviction signal is the multi-sponsor tofacitinib citrate cluster, which will accelerate revenue erosion for XELJANZ and pressure the broader JAK inhibitor class. Key risk: the lack of NME approvals in this period suggests a temporary lull in novel drug catalysts, shifting focus to competitive dynamics in established markets.

5 total filings
· daily

New Federal Contractors — June 10, 2026

This digest covers five contracts totaling $1.18 billion, with a clear civilian tilt (3 of 5 awards) and a dominant theme of professional services for federal R&D and healthcare programs. The highest-conviction signal is CACI International's $777M special operations support award, a fully competitive win that underscores its moat in high-priority defense services, though the cost-plus structure caps margin upside. A key risk is the negative outlay on Amentum Services' $92M GSA delivery order, which may indicate funding timing issues or execution friction. The digest reveals no direct investable exposure to the $125M Mount Sinai or $92M Caltech awards, as both are nonprofits, limiting actionable equity implications for those contracts.

5 total filings
· daily

Significant Contract Modifications ($10M+) — June 10, 2026

Over the period, $1.18B in significant contract modifications were awarded, with 2 of 5 contracts defense-related, but the defense-focused awards carry the highest investment conviction. The dominant theme is high-priority defense services and special operations support, led by CACI International Inc.'s $777M delivery order for Special Operations Forces support at Fort Bragg—this is the highest-conviction signal, representing 66% of total obligation value and reflecting a clear competitive moat in a multi-year, high-priority mission area. However, the civilian awards include a $125.5M cost-no-fee CDC contract that has already ended and a $92.8M BARDA biotech consulting contract to a private firm, limiting direct investment avenues. A key risk is Amentum Services' $91.7M GSA contract showing negative outlays, suggesting funding timing issues or payment delays that warrant close monitoring.

5 total filings
· daily

Contract Deobligations Alert — June 10, 2026

This digest covers $1.18 billion in government contract obligations from June 10, 2026, with a 2/5 defense-related split and an average signal strength of 5.2/10. The dominant theme is civilian agency spending on specialized professional services, led by a $777M CACI NSS award from GSA for special operations support—the highest-conviction bullish signal. However, three of five contracts are neutral, reflecting limited direct investability (Icahn School of Medicine, Caltech/JPL, private Tunnell Consulting). Key risks include execution uncertainty on Amentum’s $91.7M award (negative outlays) and the cost-plus structure capping margin upside on CACI’s contract. Investors should watch option exercises on CACI’s $1.13B potential value and monitor BARDA’s biodefense spending trajectory for follow-on opportunities.

5 total filings
· daily

Federal Professional Services Contracts — June 10, 2026

The three federal professional services contracts awarded between June 10, 2026, and June 10, 2026, total $961.9 million, with a clear defense tilt (2 of 3 contracts, or 67% by count and 90% by value). The dominant theme is high-priority defense support, led by CACI International Inc.'s $777.4 million special operations support contract from GSA, which represents 81% of aggregate value and carries the strongest bullish signal. Amentum Services, Inc. adds a $91.7 million engineering support award, reinforcing defense services demand, while the sole civilian contract—a $92.8 million BARDA award to private Tunnell Consulting Inc.—signals sustained biodefense investment but offers no direct public equity exposure. Key risks include CACI's cost-plus pricing limiting margin upside and Amentum's negative outlays suggesting funding timing uncertainty. The highest-conviction signal is CACI's competitive win in a full-and-open competition, validating its moat in special operations support.

3 total filings
· daily

NASA & Space Contracts Intelligence — June 10, 2026

This digest covers a single $92.5M NASA contract awarded to the California Institute of Technology (Caltech) for operating its Jet Propulsion Laboratory (JPL) as a Federally Funded Research and Development Center (FFRDC) focused on high-performance spaceflight computing R&D through 2026. The contract is entirely civilian (NASA), non-competitive, and cost-plus-fixed-fee, indicating stable, low-risk funding for a private nonprofit entity with no direct public equity exposure. The highest-conviction signal is neutral: the award reinforces NASA’s long-term commitment to FFRDC-based space computing R&D, which indirectly benefits publicly traded defense/space contractors through subcontracting or follow-on work. A key risk is the lack of direct investable exposure, as Caltech is private, and the contract’s materiality to public markets is low. Investors should watch for any shift away from the FFRDC model toward competitive awards post-2026, which could open opportunities for commercial space computing firms.

1 total filings
· daily

All HHS Contracts — June 10, 2026

The two HHS contracts totaling $218.2 million reveal a civilian-focused procurement stream with a biodefense and public health services tilt, though only one of the two is defense-related (BARDA). The highest-conviction signal is Tunnell Consulting Inc.'s $92.8 million BARDA delivery order (potential $660.2M with options through 2035), indicating sustained government investment in biotech R&D and pandemic preparedness, but the company is private, limiting direct equity exposure. The Icahn School of Medicine's $125.5 million CDC contract is a low-margin, cost-no-fee award that has already ended, offering no future revenue upside. Key risk: Tunnell's labor-hours pricing structure shifts cost overrun risk to the contractor, and the Icahn contract's outlay rate is only 26% of the total obligation, suggesting potential under-execution or budget constraints.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — June 10, 2026

This digest covers two contracts totaling $902.9M in obligations, with a clear split: one $777.4M defense-related award to CACI International for special operations support (bullish, high materiality) and one $125.5M civilian health services contract to Icahn School of Medicine (neutral, low materiality, already expired). The dominant theme is defense services resilience, driven by CACI's competitive win in a high-priority DOD niche, though the cost-plus pricing structure limits margin expansion. The key risk is the expired Mount Sinai contract, which provides no forward revenue, and the need to monitor CACI's option exercises for sustained growth. Overall, the digest signals a modestly bullish tilt for defense services contractors, with CACI as the primary actionable name.

2 total filings
· daily

High-Value Federal Grants ($5M+) — June 10, 2026

This digest covers $1.18B in high-value federal contracts awarded on June 10, 2026, with a 2/5 defense-related split, though the largest award—a $777M CACI NSS delivery order for special operations support—dominates the aggregate. The civilian side is led by a $125.5M Icahn School of Medicine CDC contract (now expired) and a $92.8M BARDA award to private firm Tunnell Consulting for biodefense R&D, signaling sustained biosecurity investment. The highest-conviction signal is the CACI award, which is bullish for defense services given its full-and-open competitive win and high-priority mission, but the cost-plus structure limits margin upside. Key risks include the negative outlay on the Amentum $91.7M GSA contract, suggesting funding timing uncertainty, and the expiration of the Icahn contract, which removes a revenue stream. Investors should watch for option exercises on CACI's $1.13B potential ceiling and Tunnell Consulting's long-dated BARDA options extending to 2035.

5 total filings
· daily

General Federal Contracts — June 10, 2026

The five contracts analyzed total $1.18 billion, with two defense-related awards (CACI and Amentum) accounting for $869 million of the aggregate, underscoring sustained DOD and GSA demand for special operations and engineering support. The dominant theme is civilian agency spending on biodefense and healthcare services, led by a $125.5M CDC award to Icahn School of Medicine and a $92.8M BARDA delivery order to Tunnell Consulting. The highest-conviction signal is CACI’s $777M special operations support contract, which validates its competitive moat in high-priority defense niches despite cost-plus margin constraints. A key risk is the negative outlay adjustments on both the CACI and Amentum contracts, which may indicate early-stage funding timing issues or administrative delays that could pressure near-term cash flows.

5 total filings
· daily

All NASA Contracts — June 10, 2026

The sole NASA contract awarded in this period, a $92.5M non-competitive delivery order to the California Institute of Technology for Jet Propulsion Laboratory operations, represents a wholly civilian, non-commercial investment signal. With zero defense-related obligations, the digest provides no actionable publicly traded company exposure, though it underscores sustained long-term NASA R&D investment in high-performance spaceflight computing. The neutral signal strength (3/10) and low materiality (2/10) render this digest uninformative for institutional positioning. Key risk remains the non-investable nature of the recipient and potential post-2026 funding uncertainty for JPL's FFRDC model.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — June 10, 2026

The 14 filings for the S&P 500 Technology stream reveal a sector bifurcated between AI-driven growth and legacy business erosion. Oracle's record Q4, with cloud IaaS surging 93% YoY and RPO hitting $638B, underscores the massive capital rotation into AI infrastructure, though negative free cash flow of -$23.7B highlights the cost. In contrast, the software segment declined 2% YoY, confirming the secular shift from on-premise to cloud. Outside of tech, a proxy battle at Genco Shipping (GNK) is intensifying, with all three proxy advisors backing the board against a below-NAV tender offer. Capital-raising activity is visible at Blockchain Digital Infrastructure ($55M offering) and Aditxt's planned spin-off of Ignite Proteomics at a $150M valuation. Insider activity is sparse, but the high shareholder turnout (85%) and near-unanimous votes at ImmunityBio suggest strong management support. The key portfolio-level pattern is the 'AI investment tax': companies are sacrificing near-term cash flow for long-term cloud and AI infrastructure dominance, creating a divergence between GAAP and non-GAAP profitability.

4 high priority 10 medium 14 total filings
· daily

Nasdaq 100 Stocks SEC Filings — June 10, 2026

The 15 filings for the NASDAQ-100 stream reveal a market dominated by a high-stakes proxy battle at Genco Shipping, where all three proxy advisors back management against Diana Shipping's inadequate tender offer, signaling a potential value unlock if shareholders side with the board. Capital allocation trends are mixed: Amazon has secured a massive $17.5 billion term loan for general corporate purposes, suggesting aggressive reinvestment, while ImmuCell is pivoting its manufacturing strategy with a $3.5 million expansion. Insider activity is sparse, but the QumulusAI filing shows a significant executive shake-up with new CEO incentives tied to a Nasdaq listing. Forward-looking data points to a catalyst-heavy period, with Genco's annual meeting on June 18 and Aditxt's planned spin-off of Ignite Proteomics. Overall, the filings indicate a bifurcated market where activist-driven value plays (Genco) and capital-intensive growth strategies (Amazon, Aditxt) coexist with routine governance and operational updates from smaller caps, offering selective opportunities for active investors.

5 high priority 10 medium 15 total filings
· daily

S&P 500 Financials Sector SEC Filings — June 10, 2026

The 50 filings for the S&P 500 Financials sector reveal a sector bifurcated between strong capital returns and operational caution. A clear theme is aggressive capital deployment, with major buyback authorizations from News Corp ($1B) and Ensign Group ($40M), alongside significant debt refinancing by Rocket Companies ($1.5B) and Hut 8 Corp ($4.25B) to fund growth. However, this is contrasted by a wave of M&A activity, including the transformative Paramount Skydance/WBD merger nearing completion and the Corebridge/Equitable merger progressing, signaling industry consolidation. Period-over-period data shows mixed results: Chewy delivered strong 7.7% revenue growth and 51.9% net income expansion, while J.Jill saw a 6% sales decline and 38.8% Adjusted EBITDA drop. Insider activity is sparse but notable, with a lack of insider buying in the face of significant stock-based compensation at Chewy. Forward-looking statements are cautiously optimistic, with Elevance Health reaffirming guidance and Core & Main projecting 2-3% sales growth, but the broader economic uncertainty is reflected in mixed sentiment across many filings. The most critical development is the pending closure of the Paramount Skydance/WBD merger, which could reshape the media landscape, and the successful completion of the Einride/Legato SPAC deal, signaling continued appetite for high-growth tech in the financial sector.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — June 10, 2026

This batch of 42 S&P 500 Consumer Staples filings reveals a sector in transition, with a clear divergence between companies successfully navigating input cost inflation and those facing margin compression. While the sector shows no uniform growth pattern, several key themes emerge: a wave of capital market activity (debt offerings, SPAC extensions, and IPOs), a focus on operational efficiency and capacity expansion, and mixed signals from insider activity. The most critical developments include a major regulatory win for Clover Health (Star Rating upgrade to 4.5) and a significant asset sale by Braemar Hotels & Resorts ($437.5M). However, the lack of robust period-over-period comparisons in many filings limits the ability to identify broad sector-wide trends, making company-specific catalysts and risks the primary drivers of actionable intelligence. The overall sentiment is cautiously optimistic, with opportunities in companies executing on strategic shifts and risks in those with high debt loads or shareholder dissent.

16 high priority 26 medium 42 total filings